AVLN · Avalyn Pharma

The thesis

Avalyn Pharma's shares are more likely to lag the S&P 500 over the next three months. The inhaled-antifibrotic case has no efficacy readout until the Phase 2b MIST trial reports in the second half of 2027, and the third-quarter report on 12 November 2026 added no new clinical data. The company's next appearance is a London investor conference on 18 November 2026; the MIST topline is what settles the case.

The third-quarter release showed a net loss of $29.7 million against $23.6 million a year earlier. Cash, cash equivalents and marketable securities were $386.6 million at 30 September 2026, and the company again said funding lasts into 2029. MIST and AURA (the AP02 trial) timing was unchanged, and the AP03 Phase 1 study has started, ahead of the end-of-2026 guide.

The shares closed at $30.59 on 12 November 2026, above the 50-day moving average of $28.77, and were 22.1% lower than three months earlier. The price already reflects a funded path to data: with $386.6 million of cash at 30 September 2026, the value the market gives AP01 and AP02 rests on trial results that are about a year away. The rating is Low because the next datapoint that can widen that gap falls outside a three-month window.

Bullish and bearish views on Avalyn Pharma Inc.

The bull case on Avalyn Pharma Inc. (AVLN), in brief: funding covers Phase 3 plans. The bear case: no efficacy data for about a year.

Bull case

• Funding covers Phase 3 plans. The 12 November 2026 release said cash of $386.6 million is sufficient to fund operations into 2029. At the Guggenheim conference on 10 November 2026, management said the runway includes Phase 3 programs for AP01 and AP02 (Investing.com transcript summary).
• MIST enrolled above target. MIST randomized 398 patients against a 375 target, per the 12 August 2026 second-quarter release. Its primary endpoint is change in forced vital capacity (FVC), a measure of lung function. Results remain guided to the second half of 2027.
• The third program is moving. The 12 November 2026 release said the AP03 Phase 1 healthy-volunteer study, an inhaled pirfenidone and nintedanib combination, has started with at least 32 participants and was cleared to proceed in Australia. Results are guided to the second half of 2027.
• Analyst targets sit well above the price. Raymond James initiated at Outperform with a $60 target on 2 October 2026. Morgan Stanley raised its target from $53 to $57 on 13 August 2026. MarketBeat's tally on 9 November 2026 showed a Moderate Buy consensus and a $60.00 average target.

Bear case

• No efficacy data for about a year. MIST topline is guided to the second half of 2027, and AURA results to late 2027. Until then the shares move on stock supply, conference remarks and sell-side commentary.
• Spending is rising. Third-quarter research and development expense was $25.5 million against $22.1 million a year earlier. General and administrative expense was $7.6 million against $3.2 million, on headcount and stock-based compensation (12 November 2026 release).
• A 10% holder is selling. Fmr LLC reported an open-market sale of 228,454 shares at an average of $29.33 on 9 November to 10 November 2026 (SEC Form 4, filed 12 November 2026). The 180-day IPO lock-up ended on 26 October 2026, so other pre-IPO holders can also sell.
• The shares are well below their summer highs. The shares closed at $39.25 on 14 August 2026 and $37.39 on 4 September 2026, and the three-month change to 12 November 2026 was −22.1%.

Price setup

The shares closed at $30.59 on 12 November 2026, down from $31.62 on 11 November 2026. The 50-day moving average was $28.77 as of the 12 November 2026 close. Over the past three months, closes ranged from $39.25 on 14 August 2026 to $24.64 on 15 October 2026, so the latest close sits in the lower middle of that range.

The 9 November 2026 gap is the most recent marker. The shares opened at $30.74 that day after a $26.67 prior close, and MarketBeat gave no cause. The Fmr sale prices of $29.06 to $30.28 fell inside the gap-up range. A move back toward the $26.67 close would undo the gap. The $18.00 IPO price of 30 April 2026 is the lowest reference in the listing history.

Catalysts ahead

• 18 November 2026: Company presentation at a London healthcare investor conference. This is the first company appearance after the third-quarter report and may update MIST, AURA and AP03 timing and spending.
• 1 December 2026: Company presentation at a Miami healthcare investor conference. Another chance for updates on AP03 Phase 1 progress and on spending ahead of the 2027 readouts.
• 2H 2027: MIST Phase 2b topline for AP01 (company guidance). The FVC result decides whether the inhaled-reformulation case carries value and sets the AP01 Phase 3 path.

What would change the view

A daily close above $39.25, the 14 August 2026 close and the highest of the past three months, which would show the shares leading the S&P 500 and prove this lag call wrong.

What it trades with

AVLN has no product revenue. It trades on its own clinical calendar and on small- and mid-cap biotech risk appetite more than on any sales line. Near-term company drivers are the conference presentations on 18 November 2026 and 1 December 2026 and sales by unlocked holders.

The market for idiopathic pulmonary fibrosis (IPF) treatments shapes how investors value the inhaled approach. At Guggenheim on 10 November 2026, management cited a $4 billion global franchise for oral nintedanib (OFEV) and about 300,000 diagnosed US IPF patients. It also cited roughly $200,000 per year of treatment as the price of Boehringer's newly launched JASCAYD. Launch updates from oral competitors bear on how much tolerability gain an inhaled drug needs to show.